{
    "organizations": [],
    "uuid": "55a931d32234bb860ad226e1e300c67f1c012bb8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-veru-q1-loss-per-share-008/brief-veru-q1-loss-per-share-0-08-idUSASB0C5M1",
    "ord_in_thread": 0,
    "title": "BRIEF-Veru Q1 Loss Per Share $0.08",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Veru Inc:\n* VERU REPORTS FISCAL 2018 FIRST-QUARTER FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.08 * Q1 REVENUE $2.6 MILLION VERSUS $3.2 MILLION * REMAIN ON TRACK TO FILE WITH FDA COMPANYâ€˜S FIRST NDA FOR TAMSULOSIN DRS IN 2018\n* PLAN TO SUBMIT TWO ADDITIONAL NDAS IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T19:36:00.000+02:00",
    "crawled": "2018-02-15T20:57:37.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "veru",
        "inc",
        "veru",
        "report",
        "fiscal",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "million",
        "remain",
        "track",
        "file",
        "fda",
        "company",
        "first",
        "nda",
        "tamsulosin",
        "drs",
        "plan",
        "submit",
        "two",
        "additional",
        "ndas",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}